Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI - ScienceDirect
Frontiers | Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update | Cardiovascular Medicine
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation | NEJM
Subgroup Analysis from the RE-DUAL PCI Trial | tctmd.com
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation | Challenges in Cardiology
REDUAL PCI dual antithrombotic therapy with dabigatran after
Switching of oral anticoagulation therapy after PCI in patients with atrial fibrillation: The RE-DUAL PCI trial subanalysis
AF and PCI in Practice. - ppt download
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
PDF) Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
![AHA2017]RE-DUAL PCI：达比加群双疗治疗亚组分析，获益依旧】-中华医学网-183](http://medline.org.cn/ueditor/jsp/upload/image/20171116/1510827731603053890.png "AHA2017]RE-DUAL PCI：达比加群双疗治疗亚组分析，获益依旧】-中华医学网-183")
AHA2017]RE-DUAL PCI：达比加群双疗治疗亚组分析，获益依旧】-中华医学网-183
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation | NEJM
PDF) Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in
Specified subanalysis of the RE-DUAL PCI trial | boehringerone.com
Superior safety of dual therapy with dabigatran and clopidogrel vs. triple therapy with warfarin, aspirin and clopidogrel in the RE-DUAL PCI trial: What is key, the strategy or the drug? | Semantic
RE-DUAL OAC switching subanalysis animated video | boehringerone.com
Superior safety of dual therapy with dabigatran and clopidogrel vs. triple therapy with warfarin, aspirin and clopidogrel in the RE-DUAL PCI trial: What is key, the strategy or the drug? - European
Switching of OAC After PCI in A-fib Patients:RE-DUAL PCI Trial Subanalysis | tctmd.com
Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy | AETOSWire
Dalla non inferiorita alla superiorita i NAO sono
Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial - EuroIntervention
The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status | tctmd.com
Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement | Business Wire
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation | Challenges in Cardiology
Atrial Fibrillation and PCI - ppt download
